Full Breakdown
Merck’s Upcoming Q2 2026 Earnings: Revenue Beat, Guideline Lift, and Profit-Guidance Cut
8/4/2026, 8:40:22 PM
Core Event – Scheduled August 4 Release
Merck (MRK.N) is scheduled to release its second-quarter 2026 earnings on August 4. The company anticipates quarterly revenue of $16.61 billion, a 5 % increase from the same period a year earlier and above the LSEG consensus estimate of $16.36 billion. Adjusted earnings are projected at $2.66 to $2.76 per share, reflecting a one-time $5.7 billion charge tied to the acquisition of Terns Pharmaceuticals and a $9 billion charge related to the earlier purchase of Cidara Therapeutics.
Key product sales expected for the quarter include:
- Keytruda (pembrolizumab) – $8.37 billion, up 5 % YoY, with $463 million from the newer subcutaneous formulation Keytruda QLEX.
- Winrevair – $588 million, up 75 % YoY.
- Capvaxive (pneumococcal vaccine) – $184 million, up 42 % YoY.
- Animal-health segment – $1.78 billion, an 8 % rise.
Merck will also raise its full-year 2026 revenue outlook to $66.3 billion – $67.3 billion, up from the prior range of $65.8 billion – $67.0 billion.
Background & Context – Acquisitions and Patent Landscape
Merck has pursued a series of acquisitions to offset generic competition for drugs such as Januvia, Janumet, and the flagship immunotherapy Keytruda, whose primary patents expire beginning in 2028. The Terns Pharmaceuticals deal adds experimental oncology assets, while the Cidara Therapeutics purchase brings a pipeline that includes a PCSK9 cholesterol-lowering pill approved in July. The sizable acquisition-related charges are the primary drivers of the lowered adjusted-earnings guidance.
Data & Statistics – Quarter Highlights
| Metric | Figure |
|---|---|
| Revenue (expected) | $16.61 billion |
| Revenue growth YoY | 5 % |
| Keytruda sales | $8.37 billion (incl. $463 million QLEX) |
| Winrevair sales | $588 million |
| Capvaxive sales | $184 million |
| Animal-health sales | $1.78 billion |
| Adjusted EPS guidance | $2.66 – $2.76 |
| One-time Terns charge | $5.7 billion ($2.31 per share) |
| One-time Cidara charge | $9 billion ($3.62 per share) |
Verbatim Quotes
- “The data that we access suggest that the overall vaccines market in the United States has declined,” — Financial Officer Caroline Litchfield
Why It Matters – Outlook and Market Implications
The anticipated revenue beat demonstrates the continued strength of Merck’s oncology franchise, particularly the newer QLEX formulation that is gaining market share ahead of Keytruda’s patent expirations. However, the substantial acquisition-related charges compress short-term profitability, prompting a lowered adjusted-earnings outlook. Investors will watch the actual results on August 4 to gauge whether the projected revenue growth and vaccine-market resilience materialize as expected.
